Compare VINP & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VINP | LXRX |
|---|---|---|
| Founded | 2009 | 1995 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 638.8M | 703.3M |
| IPO Year | 2020 | 2000 |
| Metric | VINP | LXRX |
|---|---|---|
| Price | $9.79 | $2.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $14.00 | $4.15 |
| AVG Volume (30 Days) | 62.3K | ★ 4.4M |
| Earning Date | 05-11-2026 | 05-01-2026 |
| Dividend Yield | ★ 5.72% | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | $18.07 | N/A |
| Revenue Next Year | $12.74 | N/A |
| P/E Ratio | $24.41 | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $9.20 | $1.00 |
| 52 Week High | $13.61 | $2.68 |
| Indicator | VINP | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.65 | 55.58 |
| Support Level | $9.61 | $1.50 |
| Resistance Level | $10.24 | $2.61 |
| Average True Range (ATR) | 0.37 | 0.16 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 13.14 | 45.89 |
Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.